Vortioxetine treatment for major depressive disorder with the co-morbidity of irritable bowel syndrome with diarrhoea: a case report
Irritable bowel syndrome (IBS) is a complex condition that involves problems with bowel movements and belly pain, bloating, and gas. It is not life threatening, but can be a long-lasting problem that changes life quality. Several studies have shown that up to 70–90% of patients with IBS who seek tre...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AVES
2018-01-01
|
| Series: | Psychiatry and Clinical Psychopharmacology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/24750573.2017.1387403 |
| Summary: | Irritable bowel syndrome (IBS) is a complex condition that involves problems with bowel movements and belly pain, bloating, and gas. It is not life threatening, but can be a long-lasting problem that changes life quality. Several studies have shown that up to 70–90% of patients with IBS who seek treatment have psychiatric co-morbidity, most notably mood and anxiety disorders. There are different approaches in the medication for IBS. Antidepressants such as tricyclic antidepressants and selective serotonin reuptake inhibitors are shown to be useful in the treatment. Vortioxetine may become a possible new agent in the treatment of patients with major depressive disorder and IBS with diarrhoea co-morbidity. |
|---|---|
| ISSN: | 2475-0573 2475-0581 |